Embedding textile capacitive sensing into smart wearables as a versatile solution for human motion capturing.

This work presents a novel and versatile approach to employ textile capacitive sensing as an effective solution for capturing human body movement through fashionable and everyday-life garments. Conductive textile patches are utilized for sensing the movement, working without the need for strain or direct body contact, wherefore the patches can sense only from their deformation within the garment. This principle allows the sensing area to be decoupled from the wearer's body for improved wearing comfort and more pleasant integration. We demonstrate our technology based on multiple prototypes which have been developed by an interdisciplinary team of electrical engineers, computer scientists, digital artists, and smart fashion designers through several iterations to seamlessly incorporate the technology of capacitive sensing with corresponding design considerations into textile materials. The resulting accumulation of textile capacitive sensing wearables showcases the versatile application possibilities of our technology from single-joint angle measurements towards multi-joint body part tracking.

Late and very late catch-up after 90Sr/90Y beta-irradiation for the treatment of coronary in-stent restenosis.

Since late vessel failure has been speculated as a significant limitation of vascular brachytherapy (VBT), we conducted a prospective clinical evaluation at 6, 12, 24, 36 and 60 months follow-up after irradiation with (90)Sr/(90)Y for in-stent restenosis (ISR) regardless of the patient's symptomatic status. Complete five-year follow-up is reported for 104 consecutive patients. The cumulative rate of death was 13.5% (6 months: 0.96%; 12 months: 2.88%; 24 months: 4.81%; 36 months: 7.69%), of acute myocardial infarction 4.81% (2.88%; 4.81%; 4.81%; 4.81%), of late thrombotic occlusion 4.81% (3.85%; 4.81%; 4.81%; 4.81%), of target lesion revascularization (TLR) 27.9% (8.65%; 12.5%; 17.3%; 21.2%), of target vessel revascularization (TVR) 43.3% (12.5%; 19.2%; 22.1%; 29.8%), and of all major adverse cardiovascular events (MACE) 61.5% (16.3%; 26.9%; 31.7%; 42.3%), respectively. Considered that the annual incidence of TVR after the first year following drug-eluting stenting for in-stent restenosis has been reported as approximately 3% per year, an incidence of 5.8% per year following VBT of our study population clearly indicates a more pronounced, delayed and, even in the fifth year after the index procedure, ongoing restenotic process following beta-irradiation of in-stent restenotic lesions associated with clinically relevant adverse cardiovascular events.